- Home
- CABO vs AUTL Comparison
CABO vs AUTL Comparison
Compare CABO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CABO | AUTL |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.5M | 376.6M |
| IPO Year | 2015 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CABO | AUTL |
|---|---|---|
| Price | $5.18 | $1.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $44.25 | $8.75 |
| AVG Volume (30 Days) | 890.4K | ★ 2.0M |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,501,423,000.00 | $10,120,000.00 |
| Revenue This Year | N/A | $98.68 |
| Revenue Next Year | $4.86 | $28.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $4.36 | $1.18 |
| 52 Week High | $138.00 | $2.58 |
Technical Indicators
Market Signals| Indicator | CABO | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 31.33 | 29.93 |
| Support Level | $4.36 | $1.38 |
| Resistance Level | $16.31 | $1.73 |
| Average True Range (ATR) | 0.85 | 0.10 |
| MACD | 0.41 | -0.01 |
| Stochastic Oscillator | 20.58 | 12.20 |
Price Performance
Historical ComparisonAbout CABO Cable One Inc.
Cable One Inc is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. The company derives majority of its revenue from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.